COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISK

被引：0

作者：

Garcia-Goni, M. ^{[1
]}

Facila, L. ^{[2
]}

Cinza, S. ^{[3
]}

Pinto, X. ^{[4
]}

Cortes, X. ^{[5
]}

Prades, M. ^{[6
]}

Aceituno, S. ^{[6
]}

机构：

[1] Univ Complutense, Madrid, Spain

[2] Hosp Gen Univ Valencia, Valencia, Spain

[3] Porto Do Son Primary Care Hlth Ctr, La Coruna, Spain

[4] Hosp Bellvitge Princeps Espanya, Lhospitalet De Llobregat, Spain

[5] Almirall SA, Barcelona, Spain

[6] Outcomes 10, Castellon De La Plana, Spain

来源：

VALUE IN HEALTH | 2018年 / 21卷

关键词：

D O I：

10.1016/j.jval.2018.09.620

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCV74

引用

页码：S104 / S105

页数：3

共 50 条

[31] THE EFFECTIVENESS OF ROSUVASTATIN IN HIGH RISK PATIENTS TREATMENT [J].

Kuznetsova, T. ;

Gavrilov, D. ;

Kirillova, A. ;

Dudanov, I. .

ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) :221-222

[32] Cost-effectiveness analysis of a cardio-oncology rehabilitation framework compared to an exercise intervention for cancer survivors with high cardiovascular risk [J].

Viamonte, Sofia G. ;

Tavares, Aida ;

Alves, Alberto J. ;

Joaquim, Ana ;

Vilela, Eduardo ;

Capela, Andreia ;

Costa, Ana Joao ;

Duarte, Barbara ;

Rato, Nuno Dias ;

Afreixo, Vera ;

Carvalho, Ricardo Fontes ;

Santos, Mario ;

Ribeiro, Fernando .

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024,

[33] Screening for second primary melanoma in high risk patients: A cost-effectiveness analysis [J].

Seth, Divya ;

Krasne, Margaret ;

James, Lyndon ;

Kim, Jane ;

Bordeaux, Jeremy .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) :AB2-AB2

[34] Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population [J].

Moreno Garcia, Marina Soledad ;

Gonzalez Mazario, Roxana ;

Uson Rodriguez, Yedra ;

Merino Ibarra, Erardo ;

Giner, Emilio ;

Cobeta Garcia, Juan Carlos ;

Arce Benavente, Marilia ;

Fabregas Canales, Maria Dolores ;

Ullier Bellmunt, Julia ;

Boselli, Giuliano ;

Martinez Valles, Pilar ;

Fragio Gil, Jorge Juan ;

Vazquez Galeano, Carlos ;

Turrion Nieves, Ana .

ARTHRITIS & RHEUMATOLOGY, 2024, 76 :4326-4328

[35] Effects of atorvastatin and rosuvastatin on renal function in patients at high cardiovascular risk: a meta-analysis of 21 randomized trials [J].

Savarese, G. ;

Volpe, M. ;

Musella, F. ;

Casaretti, L. ;

Perrone-Filardi, P. .

EUROPEAN HEART JOURNAL, 2012, 33 :950-950

[36] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND [J].

Pawlik, D. ;

Wojcik, R. ;

Zawodnik, A. ;

Kaczor, M. P. .

VALUE IN HEALTH, 2017, 20 (09) :A478-A478

[37] Rosuvastatin is more cost-effective compared to atorvastatin and simvastatin for hyperlipidemia management in high-risk patients in routine clinical practice [J].

Ohsfeldt, RL ;

Gandhi, SK ;

Fox, KM ;

Stacy, T ;

McKenney, JM .

VALUE IN HEALTH, 2006, 9 (03) :A123-A123

[38] COST-EFFECTIVENESS OF ALIROCUMAB FOR PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CV RISK [J].

Yang, M. C. ;

Tan, E. C. H. .

VALUE IN HEALTH, 2019, 22 :S128-S128

[39] The cost-effectiveness of preoperative optimisation of high risk surgical patients [J].

AN Chamberlain ;

N Harper ;

S Morris .

Critical Care, 6 (Suppl 1)

[40] THE COST-EFFECTIVENESS OF TAVI IN INOPERABLE AND HIGH RISK PATIENTS IN FRANCE [J].

Goodall, G. ;

Zemanova, B. ;

Candolfi, P. ;

Sohlberg, A. .

VALUE IN HEALTH, 2017, 20 (09) :A589-A589

← 1 2 3 4 5 →